(SRPT) Sarepta Therapeutics - Overview
Stock: Exon-Skipping Injectables, Gene Therapy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 78.3% |
| Relative Tail Risk | -30.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.05 |
| Alpha | -104.80 |
| Character TTM | |
|---|---|
| Beta | 1.497 |
| Beta Downside | 1.503 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.72% |
| CAGR/Max DD | -0.48 |
Description: SRPT Sarepta Therapeutics January 16, 2026
Sarepta Therapeutics (NASDAQ:SRPT) is a commercial-stage biopharma focused on RNA-targeted and gene-therapy modalities for rare muscular dystrophies. Its approved portfolio includes EXONDYS-51, VYONDYS-53, AMONDYS-45 (all exon-skipping antisense oligonucleotides for Duchenne muscular dystrophy, DMD) and ELEVIDYS, an AAV-based gene therapy for ambulatory pediatric DMD patients. The pipeline adds SRP-9003, a gene-therapy candidate for limb-girdle muscular dystrophy, and multiple collaborations with Roche, Arrowhead, Dyno Therapeutics and academic partners.
Key metrics as of Q4 2024: - 2023 total revenue $1.3 bn, - net loss $210 m, - cash runway into 2026; - ELEVIDYS priced at $3.2 m per dose, reflecting the premium pricing trend in gene-therapy markets; - DMD prevalence in the U.S. (~15,000 patients) provides a limited but high-margin addressable market, while broader rare-disease gene-therapy pipelines are attracting >$30 bn of venture capital in 2023, underscoring sector capital inflows. A material risk is the durability of exon-skipping efficacy and potential competition from emerging CRISPR-based therapies.
For a deeper quantitative assessment of SRPT’s valuation dynamics, you may find the analyst tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -271.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA 2.21 > 1.0 |
| NWC/Revenue: 74.61% < 20% (prev 121.1%; Δ -46.45% < -1%) |
| CFO/TA -0.07 > 3% & CFO -244.6m > Net Income -271.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (100.2m) vs 12m ago -0.21% < -2% |
| Gross Margin: 76.25% > 18% (prev 0.86%; Δ 7539 % > 0.5%) |
| Asset Turnover: 68.06% > 50% (prev 45.57%; Δ 22.49% > 0%) |
| Interest Coverage Ratio: -10.58 > 6 (EBITDA TTM -180.7m / Interest Expense TTM 21.8m) |
Altman Z'' -3.63
| A: 0.52 (Total Current Assets 2.72b - Total Current Liabilities 921.4m) / Total Assets 3.49b |
| B: -1.33 (Retained Earnings -4.64b / Total Assets 3.49b) |
| C: -0.06 (EBIT TTM -230.4m / Avg Total Assets 3.55b) |
| D: -2.14 (Book Value of Equity -4.64b / Total Liabilities 2.17b) |
| Altman-Z'' Score: -3.63 = D |
Beneish M -3.05
| DSRI: 0.71 (Receivables 541.6m/516.0m, Revenue 2.41b/1.64b) |
| GMI: 1.13 (GM 76.25% / 85.92%) |
| AQI: 0.60 (AQ_t 0.08 / AQ_t-1 0.13) |
| SGI: 1.47 (Revenue 2.41b / 1.64b) |
| TATA: -0.01 (NI -271.5m - CFO -244.6m) / TA 3.49b) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of SRPT shares?
Over the past week, the price has changed by -10.79%, over one month by -4.55%, over three months by -16.81% and over the past year by -82.13%.
Is SRPT a buy, sell or hold?
- StrongBuy: 14
- Buy: 8
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SRPT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.4 | 5.4% |
| Analysts Target Price | 21.4 | 5.4% |
| ValueRay Target Price | 20.6 | 1.4% |
SRPT Fundamental Data Overview January 29, 2026
P/S = 0.9625
P/B = 1.7598
P/EG = 159.25
Revenue TTM = 2.41b USD
EBIT TTM = -230.4m USD
EBITDA TTM = -180.7m USD
Long Term Debt = 1.04b USD (from longTermDebt, last quarter)
Short Term Debt = 10.2m USD (from shortTermDebt, last quarter)
Debt = 1.25b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 637.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.72b USD (2.32b + Debt 1.25b - CCE 851.0m)
Interest Coverage Ratio = -10.58 (Ebit TTM -230.4m / Interest Expense TTM 21.8m)
EV/FCF = -7.00x (Enterprise Value 2.72b / FCF TTM -388.8m)
FCF Yield = -14.28% (FCF TTM -388.8m / Enterprise Value 2.72b)
FCF Margin = -16.11% (FCF TTM -388.8m / Revenue TTM 2.41b)
Net Margin = -11.25% (Net Income TTM -271.5m / Revenue TTM 2.41b)
Gross Margin = 76.25% ((Revenue TTM 2.41b - Cost of Revenue TTM 573.2m) / Revenue TTM)
Gross Margin QoQ = 62.25% (prev 75.04%)
Tobins Q-Ratio = 0.78 (Enterprise Value 2.72b / Total Assets 3.49b)
Interest Expense / Debt = 0.61% (Interest Expense 7.57m / Debt 1.25b)
Taxrate = 9.79% (25.5m / 260.8m)
NOPAT = -207.9m (EBIT -230.4m * (1 - 9.79%)) [loss with tax shield]
Current Ratio = 2.95 (Total Current Assets 2.72b / Total Current Liabilities 921.4m)
Debt / Equity = 0.95 (Debt 1.25b / totalStockholderEquity, last quarter 1.32b)
Debt / EBITDA = -3.53 (negative EBITDA) (Net Debt 637.1m / EBITDA -180.7m)
Debt / FCF = -1.64 (negative FCF - burning cash) (Net Debt 637.1m / FCF TTM -388.8m)
Total Stockholder Equity = 1.34b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.66% (Net Income -271.5m / Total Assets 3.49b)
RoE = -20.31% (Net Income TTM -271.5m / Total Stockholder Equity 1.34b)
RoCE = -9.71% (EBIT -230.4m / Capital Employed (Equity 1.34b + L.T.Debt 1.04b))
RoIC = -8.49% (negative operating profit) (NOPAT -207.9m / Invested Capital 2.45b)
WACC = 7.62% (E(2.32b)/V(3.57b) * Re(11.43%) + D(1.25b)/V(3.57b) * Rd(0.61%) * (1-Tc(0.10)))
Discount Rate = 11.43% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.57%
Fair Price DCF = unknown (Cash Flow -388.8m)
EPS Correlation: 57.39 | EPS CAGR: 6.20% | SUE: 0.86 | # QB: 1
Revenue Correlation: 91.11 | Revenue CAGR: 20.02% | SUE: 1.85 | # QB: 5
EPS next Quarter (2026-03-31): EPS=0.53 | Chg30d=-0.158 | Revisions Net=-1 | Analysts=7
EPS next Year (2026-12-31): EPS=3.12 | Chg30d=+0.327 | Revisions Net=-1 | Growth EPS=+256.5% | Growth Revenue=-25.1%